What it means
CagriSema combines two molecules in one pen. Amycretin puts both actions, GLP-1 and amylin, into a single molecule. Novo Nordisk is developing it as a weekly injection under the skin and as an oral tablet.
Early-phase results published in The Lancet in 2025 reported large weight losses in small groups over 36 weeks, with mostly stomach-related side effects. Early trials are short and small, so these numbers are not directly comparable with phase 3 results for approved drugs.
In 2025 Novo Nordisk said it would move amycretin into phase 3 trials for weight management starting in 2026, with a separate program in type 2 diabetes. Approval, if it comes, would be years away.
Amycretin is not FDA-approved and is available only in clinical trials.
Why it matters
Amycretin is one of the main next-generation candidates, so you will see it in headlines well before it reaches pharmacies.
Related terms
Sources
Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error